Corbus presents pre-clinical data for obesity drug CRB-913; Phase 1 start Q1 2025

Corbus Pharmaceuticals Holdings, Inc.

CRB-913 showed 15-fold lower brain levels vs monlunabant in mice; plasma-to-brain ratio 10x better than monlunabant.
Weight loss up to 38% in DIO mice at 80 mg/kg/day over 28 days; no plateau at doses up to 80 mg/kg/day.
Switching from semaglutide to CRB-913 maintained weight loss post-withdrawal, with doubling of fat reduction vs semaglutide alone.
Human-equivalent doses range from 30 mg/day to 450 mg/day based on allometric scaling.
IND-enabling studies ongoing; first patient in Phase 1 expected in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.